FILORGA Overview
Company Headquarters: France, Europe
Founded: 1978
Workforce: ~500
Company Working: FILORGA designs and manufactures injectables used by specialists in aesthetic medicine. Its cosmetic products contain high molecular weight hyaluronic acid, encapsulated in chronospheres. Some other Filorga products contain micro-fragmented hyaluronic acid. These products are sold in more than 60 countries around the world. FILORGA’s largest markets are Italy, Spain, France, and Greater China. It provides face care, eye contour, and body care products. Colgate-Palmolive Co. (US) acquired Filorga for USD 1640.52 million in September 2019.
Strategy
FILORGA focuses on developing a diversified product portfolio by investing in developing new products. Its goal is to develop a range of cosmetic products formulated with hyaluronic acid and extend the active ingredients used in injections to new applications in the formulation of innovative cosmetics. The company is focused on implementing new ways of working and instilling a growth mindset to drive innovation with focus, empowerment, experimentation, and digitization.
